Added 1 year ago Drug news
Otsuka has announced that the FDA has approved Jynarque (tolvaptan) as the first drug treatment to slow kidney function decline...
Added 2 years ago Drug news
In the phase III, multi-center, randomized withdrawal, placebo controlled, double-blind REPRISE trial Samsca (tolvaptan), from Otsuka, slowed kidney function decline...
Added 4 years ago Drug news
NICE recommends Samsca (tolvaptan), from Otsuka, be made available for treating autosomal dominant polycystic kidney disease (ADPKD) in adults with...
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Explore the pathophysiology, epidemiology and multi-system symptoms associated with hereditary ATTR amyloidosis, as well as how to achieve an early and accurate diagnosis.
The epgonline.org team is creating daily reports from the 13th European Paediatric Neurology Society (EPNS) Congress, held in Athens, Greece from 17th to 21st September 2019, to bring you coverage of cutting-edge science and advances in clinical care across all fields of paediatric neurology.
EADV Congress 2018: Bringing you the latest news and insights from 27th EADV Congress, 12-16 September 2018 Paris, France.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations.
Standard of care therapies for autosomal dominant polycystic kidney disease (ADPKD) may limit morbidity and mortality due to disease-related complications, but they do not delay disease progression.
Added 1 year ago
Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment.
Autosomal dominant polycystic kidney disease (ADPKD) causes pathological cystic changes to the kidney and is characterized by numerous renal and systemic manifestations.
Added 1 year ago
To evaluate the prevalence and characteristics of primary nocturnal enuresis (PNE) in adults in Hong Kong, as there are currently limited epidemiological data in adults.
Added 2 years ago
I am a general urologist and men's health expert in Indianapolis, Indiana, U.S.A. I'm also an avid blogger and heath innovator. My social media brand, My Urology Doc, aims to make the formerly taboo world of urology more fun and appealing.
Men's health is a forgotten topic. To be honest, we men are mostly to blame. We've clung to our masculine misconceptions and repeatedly refused to engage the healthcare community. Who can blame us, we're invincible and we're going to live forever, right? Well, not exactly. Let's look at some of the reasons men's health is one of the least engaged topics in healthcare.